Aravive, Inc. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2021-11-12: Form 8-K; Period of report 2021-11-12; Description 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 7.01.
- 2021-11-09: Form 8-K; Period of report 2021-11-09; Description 7.01 Regulation FD Disclosure; 8.01 Other Events; Details 7.01.
- 2021-10-28: Form 8-K; Period of report 2021-10-28; Description 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; Details 2.02.
- 2021-09-10: Form 8-K; Period of report 2021-09-10; Description 5.07 Submission of Matters to a Vote of Security Holders; Details 5.07.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2021-11-12 | 8-K | 2021-11-12 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On November 12, 2021, Aravive, Inc. (the “Company”) issued a press release announcing positive new data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating batiraxcept (AVB-500) in combination with cabozantinib in patients with clear cell renal cell carcinoma (ccRCC). 8.01 On November 12, 2021, the Company issued a press release announcing positive new data from the Phase 1b portion of its open-label Phase 1b/2 trial evaluating batiraxcept (AVB-500) in combination with cabozantinib in patients with ccRCC. | arav20211111_8k.htm |
| 2021-11-09 | 8-K | 2021-11-09 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On November 9, 2021, Aravive, Inc. (the “Company”) issued a press release announcing that an abstract titled “A Phase 1b/2 randomized study of AVB-S6-500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment” that it had submitted to the Society for Immunotherapy of Cancer (SITC) in connection with its 36th Annual Meeting was published. 8.01 On November 9, 2021, the Company issued a press release announcing that an abstract titled “A Phase 1b/2 randomized study of AVB-S6-500 in combination with cabozantinib versus cabozantinib alone in patients with advanced clear cell renal cell carcinoma who have received front-line treatment” that it had submitted to the Society for Immunotherapy of Cancer (SITC) in connection with its 36th Annual Meeting was published. | arav20211108_8k.htm |
| 2021-10-28 | 8-K | 2021-10-28 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On October 28, 2021, Aravive, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2021. 7.01 The Company will be making several presentations to investors over the next several weeks. | arav20210823_8k.htm |
| 2021-09-10 | 8-K | 2021-09-10 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 On September 10, 2021, Aravive, Inc. (the “Company”) held its 2021 Annual Meeting of Stockholders (the “Annual Meeting”) at which the Company’s stockholders voted on three (3) proposals (the “Proposals”) and cast their votes as described below. | arav20210909_8k.htm |
| 2021-08-09 | 8-K | 2021-08-09 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On August 9, 2021, Aravive, Inc. (the “Company”) issued a press release announcing that it has dosed the first patient in the Phase 1b portion of its Phase 1b/2 trial of AVB-500 in combination with gemcitabine and nab-paclitaxel as a first-line treatment in patients with advanced or metastatic pancreatic adenocarcinoma. 8.01 On August 9, 2021, the Company issued a press release announcing that it has dosed the first patient in the Phase 1b portion of its Phase 1b/2 trial of AVB-500 in combination with gemcitabine and nab-paclitaxel as a first-line treatment in patients with advanced or metastatic pancreatic adenocarcinoma. | arav20210806_8k.htm |
| 2021-08-05 | 8-K | 2021-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2021, Aravive, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2021. | arav20210528_8k.htm |
| 2021-07-15 | 8-K | 2021-07-15 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On July 15, 2021, Aravive, Inc. (the “Company”) issued a press release announcing that it achieved a $3 million development milestone payment from its licensee, 3D Medicines Inc. This milestone is based on the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) approval of the Investigational New Drug (IND) application submitted by 3D Medicines Inc. to participate in the Company’s international AVB-500 Phase 3 platinum resistant ovarian cancer (PROC) clinical trial. 8.01 On July 15, 2021, the Company issued a press release announcing that it achieved a $3 million development milestone payment from its licensee, 3D Medicines Inc. This milestone is based on the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) approval of the Investigational New Drug (IND) application submitted by 3D Medicines Inc. to participate in the Company’s international AVB-500 Phase 3 platinum resistant ovarian cancer (PROC) clinical trial. | arav20210712_8k.htm |
| 2021-06-24 | 8-K | 2021-06-24 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On June 24, 2021, Aravive, Inc. (the “Company”) issued a press release announcing positive initial results from the Phase 1b portion of its Phase 1b/2 study in patients dosed with 15mg/kg of AVB-500 in combination with Cabozantinib in clear cell renal cell carcinoma. 8.01 On June 24, 2021, the Company issued a press release announcing positive initial results from the Phase 1b portion of its Phase 1b/2 study in patients dosed with 15mg/kg of AVB-500 in combination with Cabozantinib in clear cell renal cell carcinoma. | arav20210623_8k.htm |
| 2021-06-14 | 8-K | 2021-06-08 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | arav20210610_8k.htm |
| 2021-05-18 | 8-K | 2021-05-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 Effective May 12, 2021, Aravive, Inc. (the “Company”) increased the size of its Board of Directors from five directors to eight directors and Dr. Peter T. C. Ho, Dr. John A. Hohneker and Mr. Sigurd C. Kirk were appointed as members of its Board of Directors, each to hold office in accordance with the certificate of incorporation and bylaws of the Company until his successor is duly elected and qualified or his earlier death, resignation or removal. 7.01 On May 18, 2021, the Company issued a press release regarding the matters discussed in Items 5.02 above. | arav-8k_20210512.htm |
| 2021-05-06 | 8-K | 2021-05-06 | 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure | 2.02 On May 6, 2021, Aravive, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2021. 7.01 The Company will be making several presentations to investors over the next several weeks. | arav-8k_20210506.htm |
| 2021-04-27 | 8-K | 2021-04-27 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On April 27, 2021, Aravive, Inc. (the “Company”) issued a press release announcing that the Company has dosed the first patient in its Phase 3 trial of AVB-500 in platinum resistant ovarian cancer. 8.01 On April 27, 2021, the Company issued a press release announcing that the Company has dosed the first patient in its Phase 3 trial of AVB-500 in platinum resistant ovarian cancer. | arav-8k_20210427.htm |
| 2021-03-16 | 8-K | 2021-03-16 | 2.02 Results of Operations and Financial Condition | 2.02 On March 16, 2021, Aravive, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2020. | arav-8k_20210316.htm |
| 2021-03-08 | 8-K | 2021-03-08 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 On March 8, 2020, Aravive, Inc. (the “Company”) issued a press release announcing that the Company has dosed its first patient in an open label Phase 1b/2 clinical trial to evaluate the safety, pharmacokinetic, and preliminary clinical activity of AVB-500, including progression free survival. 8.01 On March 8, 2021, the Company issued a press release announcing that the Company has dosed its first patient in an open label Phase 1b/2 clinical trial to evaluate the safety, pharmacokinetic, and preliminary clinical activity of AVB-500, including progression free survival. | arav-8k_20210308.htm |
| 2021-03-02 | 8-K | 2021-03-02 | 7.01 Regulation FD Disclosure; 8.01 Other Events | 7.01 Aravive, Inc. (the “Company”) will be making several presentations to investors over the next several weeks. 8.01 The Company has announced anticipated upcoming near-term milestones that include the first patent treated in its Phase 3 clinical trial of AVB-500 in patients with platinum-resistant ovarian cancer in Q1’ 2021 and the first-patient treated in its Phase 1b study of AVB-500 in patients with ccRCC in Q1’ 2021. | arav-8k_20210302.htm |
| 2021-02-16 | 8-K | 2021-02-12 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | arav-8k_20210212.htm |
| 2021-01-27 | 8-K | 2021-01-25 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 25, 2021, Aravive, Inc. (the “Company”) entered into an amendment (the “McIntyre Amendment”), to the Offer Letter (the “McIntyre Offer Letter”) that it had entered into with Gail McIntyre, Ph.D., the Company’s Chief Executive Officer, on March 26, 2020, as amended on April 8, 2020. | arav-8k_20210125.htm |
| 2021-01-04 | 8-K | 2020-12-31 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 7.01 Regulation FD Disclosure | 5.02 On December 31, 2020, Ray Tabibiazar resigned as a director of Aravive, Inc. (the “Company”). 7.01 On December 31, 2020, the Company issued a press release regarding the matters discussed in Item 5.02 above. | arav-8k_20201231.htm |